Regencell Bioscience triples in stock price surge after 38-for-1 split

From CNBC: 2025-06-17 07:53:00

Regencell Bioscience Holdings, a Hong Kong bioscience company with no revenue, saw its shares surge over 280% after a 38-for-1 stock split. The company’s market cap is now $29.7 billion, with CEO Yat-Gai Au controlling 86.24% of shares. The surge comes amid a focus on alternative medicines and speculation in international stocks.

Regencell’s rise follows a trend of speculative international stocks gaining attention during summer trading. Earlier examples include AMTD Digital, which climbed 126% in August 2022. Regencell’s market value now rivals Nasdaq-traded Lululemon and surpasses Super Micro Computer and Fifth Third Bancorp. The stock split was aimed at increasing liquidity, not changing the company fundamentally.

Regencell’s business revolves around Traditional Chinese Medicine formulas for ADHD and autism, developed in partnership with TCM practitioner Sik-Kee Au. The company has not generated revenue or applied for regulatory approvals of its formulas, incurring net losses in recent years. Patient case studies suggest symptom improvements, but efficacy and commercialization remain unclear.

Social media buzz around Regencell shows mixed sentiment, with some users expressing enthusiasm and others skepticism. Comments on Reddit and LinkedIn range from excitement over the stock’s performance to skepticism about the company’s operations. The stock’s volatility has attracted attention, with one user nominating Regencell as “#CompleteBullsh__CompanyOfTheYear.”

Overall, Regencell’s meteoric rise in stock price, lack of revenue, and focus on alternative medicine have sparked both interest and skepticism among investors. The company’s future success and the efficacy of its treatments remain uncertain, as regulatory approvals and commercialization efforts are yet to materialize.

Read more: Hong Kong’s Regencell Bioscience triples in latest surge for a speculative stock